Trial Search Results

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sandy Srinivas

Collaborator: American Society of Clinical Oncology

Stanford Investigator(s):

Intervention(s):

  • Drug: Temsirolimus
  • Drug: Casodex (bicalutamide)

Phase:

Phase 1/Phase 2

Eligibility


INCLUSION CRITERIA

   - Histologically-confirmed adenocarcinoma of the prostate, characterized as symptomatic
   castration-resistant prostate cancer (CRPC)

   - Serum PSA ≥ 2 ng/mL

   - Rising PSA on 3 consecutive occasions at least 1 week apart (not limited to the 30-day
   screening period)

   - Failure of bilateral orchiectomy and/or therapy with an LHRH agonist and bicalutamide

   - Castrate level of testosterone (< 50 ng/dL)

   - Currently being treated with bicalutamide

   - No prior antiandrogen therapy except bicalutamide

   - Age ≥ 18 years

   - Life expectancy > 6 months

   - Performance status

      - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

      - OR

      - Karnofsky performance status ≥ 80%

   - Ability to understand and the willingness to sign a written informed consent

EXCLUSION CRITERIA

   - Radiotherapy for prostate cancer within 28 days prior to Day 1, except single-fraction
   radiotherapy for pain control

   - Prior treatment with mTOR inhibitors

   - Prior treatment with chemotherapy for prostate cancer

   - Symptomatic bone metastases (ie, asymptomatic bone metastases are eligible)

   - Visceral metastases

   - Absolute neutrophil count (ANC) < 1500/uL

   - Platelet count ≤ 100 x 10e9/L

   - Total bilirubin ≥ 1.5 x Upper Limit of Normal (ULN)

   - Alkaline phosphatase > 2.5 x ULN

   - AST > 2.5 x ULN

   - ALT > 2. 5x ULN

   - Serum creatinine > 2.0 mg/dL

   - Hemoglobin < 9 g/dL

   - Men with reproductive potential who do not agree to use an accepted and effective
   method of contraception during the study treatment period and for at least 3 months
   after completion of the study treatment

   - History of other malignancies within 5 years except for tumors with a negligible risk
   for metastasis or death, such as adequately-controlled basal cell carcinoma,
   squamous-cell carcinoma of the skin, or early-stage bladder cancer

   - Participation in another experimental drug study either planned or within 4 weeks of
   the first study treatment

   - Persistent Grade ≥ 1 AEs due to prior drug therapy, including investigational drugs,
   administered more than 14 days before study enrollment

   - Previously treated or other known brain metastases

   - Ongoing or active infection

   - Symptomatic congestive heart failure, New York Heart Association Grade II or greater

   - Unstable angina pectoris

   - Cardiac arrhythmia

   - Significant vascular disease (eg, aortic aneurysm, aortic dissection)

   - Symptomatic peripheral vascular disease

   - Psychiatric illness/social situations that would limit compliance with study
   requirements

   - Other uncontrolled intercurrent illness

   - Known to be positive for the human immunodeficiency virus (HIV) infection and
   receiving antiretroviral therapies (HIV positive not requiring antiretroviral therapy
   iseligible if all other entry criteria are meet)

   - Inability to comply with study and/or follow-up procedures

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252
Not Recruiting